Taysha Gene Therapies to Participate in Upcoming August Investor Healthcare Conferences
August 02 2021 - 7:00AM
Business Wire
BTIG Virtual Biotechnology Conference on August
9, 2021 at 11:30 am ET
2021 Wedbush Pacgrow Healthcare Virtual
Conference on August 11, 2021 at 8:35 am ET
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric,
pivitol-stage gene therapy company focused on developing and
commercializing AAV-based gene therapies for the treatment of
monogenic diseases of the central nervous system (CNS) in both rare
and large patient populations, today announced its participation in
a fireside chat for the BTIG Virtual Biotechnology Conference and a
panel for the 2021 Wedbush Pacgrow Healthcare Virtual
Conference.
Conferences Details:
Event:
BTIG Virtual Biotechnology Conference
Date:
Monday August 9, 2021
Time:
11:30 am ET
Format:
Fireside chat
Participants:
RA Session II, President, Founder and
CEO
Dr. Suyash Prasad, Chief Medical Officer
and Head of R&D
Kamran Alam, Chief Financial Officer
Event:
2021 Wedbush Pacgrow Healthcare Virtual
Conference
Date:
Wednesday August 11, 2021
Time:
8:35 am ET
Format:
Panel discussion
Participants:
RA Session II, President, Founder and
CEO
Webcasts for these conferences will be available in the “Events
& Media” section of the Taysha corporate website at
https://ir.tayshagtx.com/news-events/events-presentations. Archived
versions of the webcasts will be available on the website for 60
days.
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to
eradicate monogenic CNS disease. With a singular focus on
developing curative medicines, we aim to rapidly translate our
treatments from bench to bedside. We have combined our team’s
proven experience in gene therapy drug development and
commercialization with the world-class UT Southwestern Gene Therapy
Program to build an extensive, AAV gene therapy pipeline focused on
both rare and large-market indications. Together, we leverage our
fully integrated platform—an engine for potential new cures—with a
goal of dramatically improving patients’ lives. More information is
available at www.tayshagtx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210802005344/en/
Company Contact: Kimberly Lee, D.O. SVP, Corporate
Communications and Investor Relations Taysha Gene Therapies
klee@tayshagtx.com
Media Contact: Carolyn Hawley Canale Communications
carolyn.hawley@canalecomm.com
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Apr 2023 to Apr 2024